Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 5/17/2013
Last 10 Quotes:
What's This?
| Fiscal Q3 Ending 01/13 |
Fiscal Q2 Ending 10/12 |
Fiscal Q1 Ending 07/12 |
Fiscal Q4 Ending 04/12 |
Fiscal Q3 Ending 01/12 |
|
Sales/Revenue |
7,039 | 6,139 | 4,251 | 2,065 | 3,281 |
Cost of Goods Sold (COGS) incl. D&A |
3,651 | 3,703 | 2,024 | 934 | 2,484 |
COGS excluding D&A |
3,371 | 3,437 | 1,764 | 690 | 2,246 |
Depreciation & Amortization Expense |
280 | 266 | 260 | 244 | 238 |
Gross Income |
3,388 | 2,436 | 2,227 | 1,131 | 797 |
SG&A Expense |
8,549 | 9,493 | 9,898 | 12,021 | 11,890 |
Research & Development |
5,437 | 6,053 | 6,981 | 8,930 | 9,180 |
Other SG&A |
3,112 | 3,440 | 2,917 | 3,091 | 2,710 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
0 | 1,696 | 0 | 0 | 0 |
Non Operating Income/Expense |
0 | 0 | 0 | 10 | 9 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
8 | 44 | 1 | 2 | 6 |
Gross Interest Expense |
8 | 44 | 1 | 2 | 6 |
Pretax Income |
-4,914 | -8,753 | -7,664 | -10,882 | -11,090 |
Income Tax |
0 | 0 | 0 | 0 | 0 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-4,914 | -8,753 | -7,664 | -10,882 | -11,090 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-4,914 | -8,753 | -7,664 | -10,882 | -11,090 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
-4,914 | -8,753 | -7,664 | -10,882 | -11,090 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-4,914 | -8,753 | -7,664 | -10,882 | -11,090 |
Operational EPS |
-0.04 | -0.07 | -0.07 | -0.13 | -0.13 |
EPS (basic) |
-0.04 | -0.08 | -0.07 | -0.13 | -0.13 |
EBITDA |
-4,881 | -6,791 | -7,411 | -10,646 | -10,855 |
Depreciation & Amortization Expense |
280 | 266 | 260 | 244 | 238 |
Common Shares Outstanding |
131,489 | 109,405 | 103,283 | 83,572 | 87,149 |
Basic Shares Outstanding |
131,489 | 109,405 | 103,283 | 83,572 | 87,149 |
Diluted Shares Outstanding |
131,489 | 109,405 | 103,283 | 83,572 | 87,149 |
Diluted EPS after Extraordinary Items |
-0.04 | -0.08 | -0.07 | -0.13 | -0.13 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
-0.04 | -0.08 | -0.07 | -0.13 | -0.13 |
*Figures in thousands of U.S. Dollars except shares outstanding.
